Diligence Is About Risk, Not Just Valuation

Transaction diligence in regulated medical technology environments is less about financial modeling and more about identifying where risk resides — technically, operationally, and organizationally. Yet many diligence processes remain disproportionately focused on valuation mechanics while underweighting the product, regulatory, and quality-system factors that ultimately determine whether a deal creates or destroys value.

Where the Real Risk Lives

In medtech transactions, the most consequential risks are often embedded in areas that financial models do not capture well. Is the product's regulatory pathway secure, or are there unresolved FDA interactions that could delay or derail commercialization? Are the design controls and risk management files in order, or do they contain gaps that create exposure? Is the quality system mature enough to scale, or will post-close integration surface compliance issues?

These are not abstract questions. I have participated in transactions where product regulatory risk, insufficiently characterized during diligence, became the dominant issue post-close. The financial model was sound. The strategic rationale was clear. But the product reality on the ground was different from what the data room suggested.

Operator-Level Diligence

Effective diligence in regulated environments requires someone who has operated inside these companies — who understands how design controls actually function, how regulatory interactions unfold, and how quality system maturity manifests in day-to-day operations. This is a different lens than financial diligence, and it requires a different kind of experience.

At Heinz Ventures, transaction advisory work is grounded in this operator-level perspective. The goal is not to replace financial diligence but to complement it with the kind of product, regulatory, and organizational assessment that distinguishes informed transactions from hopeful ones.